When to Suspect Cancer in a Child: Warning Signs by Organ System

For relapsed ALL, inotuzumab and blinatumomab are both available. Inotuzumab is the more affordable option since it only requires day-care admission, roughly 10,000 to 12,000 US dollars per cycle (day 1, 8 and 15), and some manufacturers offer buy-one-get-one support schemes. Blinatumomab is costlier, at 30 to 40 lakh Indian rupees, because it requires 28 days of hospitalization with continuous infusion, so it is used far less often for international patients. Anti-GD2 therapy (dinutuximab) for neuroblastoma runs around 70 to 80 lakh rupees, though the price has been coming down.

Dr. Danewa put inotuzumab at roughly 10,000 to 12,000 US dollars per cycle, noted that the 70 to 80 lakh rupee cost of dinutuximab converts to about 80,000 US dollars, and priced brentuximab plus nivolumab immunotherapy for Hodgkin lymphoma in a similar range to inotuzumab, around 12,000 to 15,000 US dollars.

Dr. Danewa explained that upfront bone marrow transplant has no role in most pediatric leukemia. It is reserved for cases without morphological remission (blasts above 10% at the end of induction), for hypodiploidy (fewer than 44 chromosomes), or for relapse. For benign conditions, the leading indication, especially in Africa, is sickle cell disease, where earlier transplant, ideally before age 12 and before pain crises, stroke or chest syndrome accumulate, gives a better outcome. He described three transplant types: matched sibling, matched unrelated donor via registry, and haploidentical transplant from a parent, with haploidentical success running around 70 to 80% depending on the underlying disease.

Yes. Dr. Danewa confirmed bone marrow transplant is a cure for sickle cell disease, and that outcomes are best the earlier it is done, since delay allows organ damage and comorbidities to accumulate and lowers the chance of success.

In relapsed or refractory leukemia, where prior treatment options offered only a 5 to 10% chance of success, both Western data and four to five years of follow-up on India's own indigenous CAR T-cell programs are now showing 50 to 60% success.

No. Prolonged fever, enlarged lymph nodes and other common signs can just as easily point to an ordinary childhood illness. What should raise suspicion is a symptom that persists longer than expected, grows more intense than routine treatment would explain, or appears in combination with other signs without a clear diagnosis.

A white reflex seen in a photograph, known as leukokoria, can be an early sign of retinoblastoma.

Leukemia crowds out the bone marrow's normal function rather than forming a single mass, producing a cluster of signs together: recurrent fever from a shortage of infection-fighting white cells, unexplained bruising or bleeding spots from low platelets, and pallor from low hemoglobin. That combination, rather than any one sign alone, should prompt a complete blood count and, if warranted, a bone marrow examination.

Early morning headaches paired with projectile vomiting point to raised intracranial pressure and a possible brain tumor.

Painless, matted lymph nodes in the neck often suggest lymphoma, distinct from the tender nodes typical of infection.